Tzu Chi Medical Journal

REVIEW ARTICLE
Year
: 2022  |  Volume : 34  |  Issue : 3  |  Page : 270--275

Hematopoietic stem cell mobilization


Hsin-Hou Chang, Yu-Shan Liou, Der-Shan Sun 
 Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan

Correspondence Address:
Der-Shan Sun
Department of Molecular Biology and Human Genetics, Tzu Chi University, 701, Zhongyang Road, Section 3, Hualien
Taiwan

Hematopoietic stem cell (HSC) transplantation has been used to treat hematopoietic diseases for over 50 years. HSCs can be isolated from bone marrow (BM), umbilical cord blood, or peripheral blood. Because of lower costs, shorter hospitalization, and faster engraftment, peripheral blood has become the predominant source of HSCs for transplantation. The major factors determining the rate of successful HSC transplantation include the degree of human leukocyte antigen matching between the donor and recipient and the number of HSCs for transplantation. Administration of granulocyte colony-stimulating factor (G-CSF) alone or combined with plerixafor (AMD3100) are clinical used methods to promote HSC mobilization from BM to the peripheral blood for HSC transplantations. However, a significant portion of healthy donors or patients may be poor mobilizers of G-CSF, resulting in an insufficient number of HSCs for the transplantation and necessitating alternative strategies to increase the apheresis yield. The detailed mechanisms underlying G-CSF-mediated HSC mobilization remain to be elucidated. This review summarizes the current research on deciphering the mechanism of HSC mobilization.


How to cite this article:
Chang HH, Liou YS, Sun DS. Hematopoietic stem cell mobilization.Tzu Chi Med J 2022;34:270-275


How to cite this URL:
Chang HH, Liou YS, Sun DS. Hematopoietic stem cell mobilization. Tzu Chi Med J [serial online] 2022 [cited 2022 Oct 2 ];34:270-275
Available from: https://www.tcmjmed.com/article.asp?issn=1016-3190;year=2022;volume=34;issue=3;spage=270;epage=275;aulast=Chang;type=0